Novartis Investigative Site

Chur 7000

0 studies enrolling now · 9 studies all time

What they study most

Adenocarcinoma, Advanced Solid Tumors, Excluding Breast Cancer, Breast Cancer, Carcinoma, Endometrial Carcinoma, Gastrointestinal Stromal Tumors, Hypernephroid, Melanoma, Neoplasms, Breast, Nephroid Carcinoma, Non Small Cell Lung Cancer, Pancreatic Carcinoma

Studies at this site

• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). — Completed
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer — Stopped early
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies — Completed
• Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors. — Completed
• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer — Completed
• Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer — Completed
• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer — APPROVED_FOR_MARKETING
• Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib — Completed